Tatyana Kushner
Hepatology · New York, NYNPI 1336463082
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $148,075 of the $180,536 with a category attached, or 82.0%. Gilead accounts for 64.9% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $51,053, 4.1 times the $12,464 reported in 2019.
Across 277 payments — averaging $651.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$117K
- GSK$21K
- Ipsen Biopharmaceuticals, Inc$12K
- AbbVie$11K
- Mirum Pharmaceuticals, Inc.$8K
- Madrigal Pharmaceuticals$5K
- plus $7K from 11 others
Across 60 payments — averaging $2362.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$134K
- AbbVie$8K
What the payments were for
- Consulting fees$148,07582%
- Speaking & faculty fees$11,5206%
- Travel & lodging$10,8646%
- Food & beverage$9,1695%
- Education$9071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 184 | $117,216 |
| GSK | 6 | $21,000 |
| Ipsen Biopharmaceuticals, Inc | 7 | $11,888 |
| AbbVie | 36 | $10,736 |
| Mirum Pharmaceuticals, Inc. | 18 | $7,820 |
| Madrigal Pharmaceuticals | 8 | $4,690 |
| Ipsen Pharma SAS | 1 | $3,320 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $3,079 |
| Intercept Pharmaceuticals, Inc. | 1 | $236 |
| Novo Nordisk | 2 | $169 |
| Eiger Biopharmaceuticals, Inc. | 1 | $104 |
| Olympus America Inc. | 1 | $102 |
| Janssen Scientific Affairs, LLC | 1 | $50 |
| Lilly USA, LLC | 1 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Orphalan Inc | 1 | $33 |
| Dynavax Technologies Corporation | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$180,536 in reported general payments places this provider in the 75th percentile of 29 hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 21 | $2,170 |
| Atorvastatin Calcium | 11 | $276 |
| Spironolactone | 14 | $101 |
| Furosemide | 14 | $41 |
| Carvedilol | 17 | $39 |
Paid to pharmacies, not to this prescriber.
Other hepatology in New York
- Robert BrownNew York$967K
- Douglas DieterichNew York$830K
- Arun JesudianNew York$828K
- Albert MinNew York$277K
- Meena BansalNew York$208K
- Howard WormanNew York$119K
- Augusto Villanueva RodriguezNew York$33K
- Jawad AhmadNew York$30K
- Joseph OdinNew York$18K
- Jennifer LeongNew York$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.